Rhythm Pharmaceuticals announced that the European Commission has granted marketing authorization for its MC4R agonist, IMCIVREE (setmelanotide), to treat acquired hypothalamic obesity (HO) in adults and children aged four years and older. The approval expands the drug’s indication beyond its existing rare‑disease indications and is a key regulatory milestone that paves the way for a commercial launch in Europe slated for 2027.
The decision was based on data from the Phase 3 TRANSCEND trial, which enrolled 120 patients in its pivotal cohort. The trial demonstrated a statistically significant 19.8% placebo‑adjusted reduction in body mass index (BMI) at 52 weeks, with 19.2% reduction in adults and 20.2% reduction in pediatric patients. The safety profile was consistent with prior studies, reinforcing the drug’s clinical value for this rare condition.
Rhythm estimates that approximately 10,000 people in Europe live with acquired HO, meaning the new indication could potentially double the company’s revenue base from its current orphan‑drug portfolio. The approval also positions Rhythm to pursue reimbursement negotiations across multiple European payers and to accelerate its global commercialization strategy for setmelanotide.
The company’s CEO, David Meeker, said, "This EC authorization is an important step toward making the first new treatment option available to people living with acquired HO in Europe. The hyperphagia and accelerated, sustained weight gain due to hypothalamic dysfunction resulting from direct injury or structural abnormality of the hypothalamus has a significant impact patients and families, who until now have had no approved treatment options. With this authorization in place, we look forward to working with local health authorities to support access for patients who may benefit throughout Europe."
Rhythm also received FDA approval for the same indication on March 19 2026, making the drug the first approved treatment for acquired HO in both the United States and Europe. The European Commission’s approval confirms the drug’s efficacy and safety profile and strengthens Rhythm’s position as a leader in rare neuroendocrine disease therapeutics.
The approval is expected to accelerate Rhythm’s commercial launch in Europe, with the company targeting a 2027 rollout and engaging with payers to secure reimbursement pathways. The expanded indication not only broadens the patient base but also enhances the company’s strategic portfolio, positioning Rhythm for sustained growth in the rare‑disease market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.